Rennes Cedex

• Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised
  2022-501562-22-00 4 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati … Not authorised
  2022-502043-35-00 5 Advanced Biliary Tract Cancers
• Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc … Not authorised
  2024-515603-19-00 4 Localized digestive Neuroendocrine Carcinomas
• LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy Pending
  2024-515340-23-00 4 Colon cancer
• Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc … Pending
  2024-515603-19-01 4 Localized digestive Neuroendocrine Carcinomas
• TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phas … Pending
  2024-516182-37-01 4 Maintenance treatment in patients with locally advanced/metastatic uro
• REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending
  2024-519298-21-00 5 Cancer-Associated Thrombosis (CAT).
• Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending
  2024-519624-24-00 4 HER3-mutant and HER2-not amplified metastatic breast cancer
• A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cance … Pending
  2024-519787-40-00 5 Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal C
• Evaluation study of a treatement with Nivolumab and Ipilimumab or tKi according to molecular group in naïve metastatic Kidney cancer Pending
  2024-520045-23-00 4 Kidney cancer
• Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending
  2025-521619-37-00 5 Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
• Clinical trial evaluating the biological activity of a new drug identified as prifetrastat (PF-07248144), combined with fulvestrant for the … Pending
  2025-521982-29-00 4 Adult patients with advanced hormone receptor positive (HR+), HER2- br
• Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan … Pending
  2025-522167-15-00 5 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• Symbiotic-GI-13, A Study to Learn About the Study Medicine Called PF-08634404 as Monotherapy and Combination Therapy in Adult Participants w … Pending
  2025-523525-17-00 9 Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
• First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of s … Pending
  2025-523593-16-00 5 Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III wel
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• Liver-directed chemotherapy after surgery of liver metastases of colorectal cancer in patients with high risk of recurrence of their disease … Pending
  2025-523913-27-00 5 Participants with R0/R1 resected liver metastases from colorectal canc
• TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending
  2025-524213-84-00 5 Patients with advanced or metastatic ER+ HER2- breast cancer
• A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending
  2025-524488-18-00 4 Muscle-invasive Bladder Cancer
• A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P … Pending
  2025-525009-18-00 5 Pancreatic Ductal Adenocarcinoma
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Recruiting
  2025-523495-23-00 5 2026-06-09 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal

Showing 1–24 of 259 trials